Did You Know...
...that in 1800 ether was first used by partyers as a fun diversion? Sniffing the gas led to hilarious and raucous laughter as people watched each other become more and more intoxicated and silly. Several doctors independently realized the value ether would have to anesthetize surgery patients. Of those who claimed rights to the "discovery," none had a happy ending. One had a seizure and died defending his rights. Another spent his life in an asylum because he had been denied acclaim. A third became addicted to chloroform and, in a New York City jail, he soaked a cloth in the drug, severed an artery and bled to death.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7666433 | Recombinant RSV strains with altered G protein The construction of recombinant respiratory syncytial virus (RSV) strains deleted of the region of G protein most likely to induce unwanted type 2 T cell responses in susceptible recipients is disclosed. Using reverse genetics, recombinant RSV strains were engineere... | 02/23/2010 |
| 7615229 | Mutants of the P4 protein of nontypable with reduced enzymatic activity A P4 variant protein that has reduced enzymatic activity and that induces antibody to wild-type P4 protein and/or has good bactericidal activity against non-typable H. influenzae (NTHi) is useful as an active component in an immunogenic composition for humans... | 11/10/2009 |
| 7611721 | Adjuvant combination formulations The use of 3-O-deacylated monophosphoryl lipid A or monophosphoryl lipid A and derivatives and analogs thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12 is useful as an adjuvant combinati... | 11/03/2009 |
| 7556940 | Assembly of wild-type and chimeric influenza virus-like particles (VLPs) Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA, NA and M2. VLPs with HA from one influenza subtype and NA from a diff... | 07/07/2009 |
| 7384640 | Mutant cholera holotoxin as an adjuvant A mutant cholera holotoxin featuring a point mutation at amino acid 29 of the A subunit, wherein the glutamic acid residue is replaced by an amino acid other than aspartic acid, is useful as an adjuvant in an antigenic composition to enhance the immune response in a... | 06/10/2008 |
| 6841160 | Meningococcal vaccines formulated with interleukin-12 This invention pertains to vaccine compositions comprising a mixture of antigen, such as pneumococcal or meningococcal antigen, and interleukin IL-12, which may be adsorbed onto a mineral in suspension. The pneumococcal or meningococcal antigen may be conjugated to ... | 01/11/2005 |
| 6709658 | Pneumococcal vaccines formulated with interleukin-12 This invention pertains to vaccine compositions comprising a mixture of antigen, such as a pneumococcal or meningococcal antigen, and interleukin IL-12, which may be adsorbed onto a mineral in suspension. The pneumococcal or meningococcal antigen may be conjugated t... | 03/23/2004 |
| 6673572 | Methods for rescue of RNA viruses This invention relates to improved methods for producing nonsegmented, negative-sense, single-stranded RNA viruses of the Order designated Mononegavirales virus, including embodiments relating to methods of producing such viruses as attenuated and/or infe... | 01/06/2004 |
| 6488936 | Immunogenic composition of interleukin-12 (IL-12), alum, herpes simplex viral (HSV) antigen, and method thereof This invention pertains to vaccine compositions comprising a mixture of antigen, such as a herpes simplex virus antigen, and the interleukin IL-12, which may be adsorbed onto a mineral in suspension. These vaccine compositions modulate the protective immu... | 12/03/2002 |
| 6420134 | Vaccines for nontypable haemophilus influenzae Protein "e" of H. influenzae, a lipoprotein of approximately 28,000 daltons, has been purified and sequenced. Protein "e" and peptides or proteins having a shared epitope, can be used to vaccinate against non-typable (and typable) H. influenzae and to pre... | 07/16/2002 |
| 6221365 | NucA protein of Haemophilus influenzae A protein from H. influenzae designated NucA is isolated and purified. The NucA protein has the amino acid sequence of amino acids 26-603 of SEQ ID NO.2 or a biologically equivalent amino acid sequence thereof. Amino acids 1-25 of SEQ ID NO.2 are the sign... | 04/24/2001 |
| 5955580 | Vaccines for nontypable haemophilus influenzae Protein "e" of H. influenzae, a lipoprotein of approximately 28,000 daltons, has been purified and sequenced. Protein "e" and peptides or proteins having a shared epitope, can be used to vaccinate against nontypable (and typable) H. influenzae and to prev... | 09/21/1999 |
| 5955596 | NucA protein of Haemophilus influenzae and the gene encoding that protein A protein from H. influenzae designated NucA is isolated and purified. The NucA protein has the amino acid sequence of amino acids 26-603 of SEQ ID NO:2 or a biologically equivalent amino acid sequence thereof. Amino acids 1-25 of SEQ ID NO:2 are the sign... | 09/21/1999 |
| 5897867 | Efficacious vaccines against Bordetella pertussis comprising a combination of individually purified pertussis antigens This invention is directed to a vaccine for the prevention of disease caused by Bordetella pertussis which comprises the pertussis antigens filamentous hemagglutinin, detoxified lymphocytosis promoting factor and a 69 kilodalton outer membrane protein, wh... | 04/27/1999 |
| 5895655 | Efficacious vaccines against Bordetella pertussis comprising a combination of individually purified pertussis antigens This invention is directed to a vaccine for the prevention of disease caused by Bordetella pertussis which comprises the pertussis antigens filamentous hemagglutinin, detoxified lymphocytosis promoting factor and a 69 kilodalton outer membrane protein, wh... | 04/20/1999 |
| 5885587 | Efficacious vaccines against Bordetella pertussis comprising a combination of individually purified pertussis antigens This invention is directed to a vaccine for the prevention of disease caused by Bordetella pertussis which comprises the pertussis antigens filamentous hemagglutinin, detoxified lymphocytosis promoting factor and a 69 kilodalton outer membrane protein, wh... | 03/23/1999 |
| 5885586 | Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens This invention is directed to a vaccine for the prevention of disease caused by Bordetella pertussis which comprises the pertussis antigens filamentous hemagglutinin, detoxified lymphocytosis promoting factor and a 69 kilodalton outer membrane protein, wh... | 03/23/1999 |
| 5780601 | Method for purification of protein "e" from haemophilus influenzae "A method of purifying protein "e" from Haemophilus influenzae includes disrupting H. influenzae cells, subjecting the disrupted cells by differential sedimentation to obtain a total cell membrane fraction, fractionating the total cell membrane into inner... | 07/14/1998 |
| 5770213 | Purified nontypable haemophilus influenzae P5 protein as a vaccine for nontypable haemophilus influenzae infection The present invention relates to P5 outer membrane protein of the non-typable Haemophilus influenzae bacterial strain and antibodies directed to P5 protein. The invention also relates to a method of isolating P5 protein and a vaccine composition for use i... | 06/23/1998 |
| 5723130 | Adjuvants for vaccines against respiratory syncytial virus Vaccine formulations and therapeutic methods therefor containing respiratory syncytial viral proteins or immunological fragment and an adjuvant selected from the group consisting of QS-21 3-deacylated monophosphoryl lipid A, monopohosphoryl lipid A and co... | 03/03/1998 |
| 5691449 | Respiratory syncytial virus vaccines Polypeptides, nucleotides, and compositions useful for preparing diagnostic reagents for and vaccines against human Respiratory Syncytial Virus are disclosed. The polypeptides include short polypeptides which are related to a neutralizing and fusion epito... | 11/25/1997 |
| 5601831 | Vaccines for nontypable Haemophilus influenzae Protein "e" of H. influenzae, a lipoprotein of approximately 28,000 daltons, has been purified and sequenced. Protein "e" and peptides or proteins having a shared epitope, can be used to vaccinate against non-typable (and typable) H. influenzae and to pre... | 02/11/1997 |
| 5565204 | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections Immunogenic polysaccharide-protein conjugates are generated which have an oxidized polysaccharide derived from the capsular polysaccharide of Streptococcal pneumniae and the pneumolysin protein of S. pneumoniae which is expressed recombinantly. The pneumo... | 10/15/1996 |
| 5547871 | Heterologous signal sequences for secretion of insect controlling proteins Seven heterologous signal sequence are described for use with genes for insect controlling proteins, such that when the signal sequence and protein genes are inserted into an insect virus, that virus demonstrates an earlier onset of morbidity than a wild-... | 08/20/1996 |
| 5270449 | Methods for the isolation of heparin-binding brain mitogens A group of growth factors, designated heparin-binding brain mitogens (HBBMs), is disclosed. The HBBMs are isolated from brain tissue by a sequence of purification steps. The growth factors may be useful in the promotion of angiogenesis, such as in the pro... | 12/14/1993 |
| 5215754 | Swallowable tablet containing polycarbophil A novel dosage form of calcium polycarbophil, useful in the treatment of bowel dysfunction, is described.... | 06/01/1993 |
| 5210180 | Enhancement of porcine somatotropin activity This invention is directed to peptide fragments of porcine somatotropin (pST) which are used to generate epitope-specific anti-pST antibodies. When such antibodies are administered with pST to warm-blooded animals, the growth enhancing activity of pST is ... | 05/11/1993 |
| 5202251 | Monocot-specific monoclonal antibodies against acetohydroxyacid synthase This invention is directed to the generation of hybridomas and the monocot-specific monoclonal antibodies prepared from those hybridomas against the acetohydroxyacid synthase enzyme. The monoclonal antibodies are useful to isolate and purify the enzyme. T... | 04/13/1993 |
| 5192540 | Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine Immunogenic conjugates of a 38,000 daltons or 40,000 daltons outer membrane protein of H. influenzae type b and oxidized polyribosyl-ribitol-phosphate polysaccharide fragments of H. influenzae type b are disclosed. Vaccines containing the conjugates are d... | 03/09/1993 |
| 5171842 | Heparin-binding brain mitogens A group of growth factors, designated heparin-binding brain mitogens (HBBMs), is disclosed. The HBBMs are isolated from brain tissue by a sequence of purification steps.... | 12/15/1992 |
| 5024948 | Genetic system for micromonospora A culture comprising the microorganism Micromonospora echinospora ssp. calichensis DR46 (ATCC-53591), which produces complementing factor, is described and disclosed.... | 06/18/1991 |
| 4968790 | Antidiabetic phosphates Phosphates are disclosed which stimulate the enzyme fructose-1,6-bisphosphatase and inhibit the enzyme 6-phosphofructo-1-kinase, thereby lowering glucose levels in mammals. These phosphates may thus be used to treat hyperglycemia and/or diabetes. Pro... | 11/06/1990 |
| 4968702 | Substituted quinolinecarboxylic acids Substituted quinolinecarboxylic acids useful in the treatment of arthritis by inhibiting the progressive joint deterioration characteristic of arthritic disease and for inducing immunosuppression are disclosed. Methods of synthesis and use of the novel co... | 11/06/1990 |
| 4945158 | Antidiabetic phosphonates Phosphonates are disclosed which stimulate the enzyme fructose-1,6-bisphosphatase and inhibit the enzyme 6-phosphofructo-1-kinase, thereby lowering glucose levels in mammals. These phosphonates may thus be used to treat hyperglycemia and/or diabetes.... | 07/31/1990 |
| 4943629 | Antidiabetic alpha-substituted phosphonates Alpha-substituted phosphonates are disclosed which stimulate the enzyme fructose-1,6-bisphosphatase and inhibit the enzyme 6-phosphofructo-1-kinase, thereby lowering glucose levels in mammals. These alpha-substituted phosphonates may thus be used to treat... | 07/24/1990 |
| 4927922 | 7ଲ-(substituted)amino-3-substituted cephalosporanic acids and esters 7ଲ-(Substituted)amino-3-substituted cephalosporanic acids, esters and salts, useful as anti-bacterial agents are described.... | 05/22/1990 |
| 4900477 | Novel intermediates and an improved process for producing the compound (3ଲ,5)-3-hydroxycholest-8(14)-en-15-one An improved process for the large scale production of the compound (3ଲ,5)-3-hydroxycholest-8(14)-en-15-one is described and two new compounds which have utility as intermediates in synthetic routes to the subject compound are disclosed.... | 02/13/1990 |
| 4900838 | Acylation products of bis(2-imidazolin-2-ylhydrazones) of 9,10-anthracenedicarboxaldehyde N-acylated derivatives of bis(2-imidazolin-2-ylhydrazones) of 9,10-anthracenedicarboxaldehyde, useful as anti-cancer agents against certain strains in mice, are disclosed and described, including processes for manufacture and use.... | 02/13/1990 |
| 4847381 | 2-Phenyl-4-quinoline carboxylic acids Substituted 4-quinoline-carboxylic acids useful in the treatment of arthritis and inhibition of progressive joint deterioration are disclosed together with methods of use and synthesis thereof.... | 07/11/1989 |
| 4833162 | Substituted benzeneacetonitriles and their use as calcium channel blockers This invention relates to novel A-[[2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]ethyl]thio]-3,4-dimethoxy -A-substituted benzeneacetonitrile compounds and a process for the preparation of said compounds. The compounds are useful as calcium channel bl... | 05/23/1989 |
